Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) | | As of | As of | | --- | --- | --- | | | June 30, | December 31, | | | 2023 | 2022 | | ASSETS | | | | CURRENT ASSETS | | | | Cash and cash equivalents | 3,031 | 23,659 | | Deposit | 13,648 | - | | Restricted deposit | 296 | 296 | | Trade accounts receivable | 118 | 78 | | Inventory | 2,751 | 2,857 | | Prepaid expenses and other receivables | 589 | 1,24 ...

IceCure Medical Ltd (NASDAQ:ICCM) Q1 2023 Earnings Conference Call May 22, 2023 10:00 AM ET Company Participants Todd Kehrli - EVC Group, IR Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - Vice President, Business Development and Global Marketing Ronen Tsimerman - Chief Financial Officer and COO Conference Call Participants Chait G - H.C. Wainwright Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning and thank you for standing by. Currently, all part ...

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Eyal Shamir - CEO Ronen Tsimerman - CFO & COO Todd Kehrli - EVC Group, IR Conference Call Participants Kemp Dolliver - Brookline Capital Markets Ben Haynor - Alliance Global Partners Chaitanya G. - H.C. Wainwright Operator Good morning, and thank you for standing by. [Operator instructions]. I would now like to turn the conference over to Todd Kehrli. Please go ahead. Todd Kehrli Thank you, Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission ...

Exhibit 99.1 IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 ● Rising Awareness and Utilization of ProSense System: System and disposables sales in the U.S. represented 20% of 2022 revenues, up from 11% in 2021, as increased utilization of systems generated a 28% year-over-year increase in U.S. sales. Worldwide, disposable sales accounted for 43% of 2022 revenue, up from 29% in 2021. ● Filed for FDA Mar ...

IceCure Medical Ltd (NASDAQ:ICCM) Q3 2022 Results Conference Call December 2, 2022 8:00 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer Hania Bednarski - Oncoplastic Breast Surgeon and Cryoablation Specialist Conference Call Participants Ben Haynor - Alliance Global Partners Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCureÂ's Conference Call on the Financial Results for the Nine Months Ended Septem ...

Exhibit 99.1 "We have edged closer to commercialization of ProSense for breast cancer in the U.S. with our recent FDA filing for marketing approval, and the assignment of a Medicare CPT III reimbursement code. IceCure has taken a leadership role in the industry based on our vast ICE 3 breast cancer cryoablation clinical data and by receiving the CMS's first payment assignment for cryoablation of breast cancer," stated IceCure's CEO Eyal Shamir. "While our quarterly revenues may continue to fluctuate in the ...

Exhibit 99.1 The accompanying notes are an integral part of the consolidated financial statements. 1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (U.S. dollars in thousands, except share data and per share data) ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) | | As of | As of | | --- | --- | --- | | | June 30, | December 31, | | | 2022 | 2021 | | ASSETS | | | | CUR ...

IceCure Medical Ltd (NASDAQ:ICCM) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Â Company Participants Eyal Shamir – Chief Executive Officer Ronen Tsimerman – Chief Financial Officer Kenneth Tomkovich – Co-Primary Investigator Conference Call Participants Ben Haynor – Alliance Global Partners Kemp Dolliver – Brookline Capital Markets Operator Welcome to IceCureÂ's Conference Call on the Financial Results for the First Half of 2022. Management will provide an overview of IceCureÂ's financial re ...

IceCure Medical Ltd. (NASDAQ:ICCM) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Richard Fine - Investigator of ICE3 Clinical Trial Conference Call Participants Ben Haynor - Alliance Global Partners Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCureÂ's First Quarter 2022 Results Conference Call. Management will provide an overview of IceCureÂ's financ ...